Roche Expands Cell Therapy Portfolio with $1.5 Billion Poseida Therapeutics Acquisition
Swiss pharmaceutical giant Roche has announced its acquisition of Poseida Therapeutics, a San Diego-based biotech company specializing in next-generation cell therapies. The deal, valued at up to $1.5 billion, is expected to close in the first quarter of 2025, and builds on an existing collaboration between the two companies in blood cancer treatments.
Kristin Yarema, President and CEO of Poseida Therapeutics:
“We have worked closely with Roche through our collaboration focused on hematologic malignancies, and we are excited to join Roche to work as colleagues together across our pipeline and future programs.”
CAR T cells attacking cancer; Credit: Prasad Adusumilli, Memorial Sloan Kettering Cancer Center
Poseida’s Cell Therapy
Poseida Therapeutics specializes in non-viral, allogeneic CAR-T therapies, which leverage T stem cell memory (TSCM)-rich platforms for enhanced cell durability and self-renewal. Their proprietary technologies include transposon-based gene editing and in-house GMP manufacturing capabilities, which aim to:
- Improve the scalability of cell therapies.
- Address safety concerns inherent in traditional viral-based approaches.
- Optimize efficacy through sustained cell activity.
Poseida’s clinical-stage programs include:
- P-BCMA-ALLO1: An allogeneic CAR-T therapy for multiple myeloma.
- P-MUC1C-ALLO1: An allogeneic CAR-T therapy targeting solid tumors.
In addition to these therapies, Poseida is advancing research on CAR-T applications for autoimmune diseases and employing its genetic engineering platform for early-stage therapeutic development.
Allogeneic CAR-T therapies, which use genetically modified donor cells rather than a patient’s own cells, are seen as a scalable, cost-effective alternative to autologous approaches.
Topic: Biotech Ventures
